IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2025 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 12.810-13.010 for the period, compared to the consensus EPS estimate of 12.620. The company issued revenue guidance of $4.3 billion-$4.3 billion, compared to the consensus revenue estimate of $4.2 billion.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday. Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research report on Friday, August 15th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $716.50.

IDEXX Laboratories Stock Up 14.8%

NASDAQ:IDXX opened at $722.94 on Tuesday. The company’s 50 day moving average is $639.53 and its two-hundred day moving average is $571.97. The company has a market cap of $57.84 billion, a PE ratio of 60.19, a P/E/G ratio of 4.06 and a beta of 1.58. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories has a twelve month low of $356.14 and a twelve month high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.14 by $0.26. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts anticipate that IDEXX Laboratories will post 11.93 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Sharon E. Underberg sold 5,450 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,200 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the transaction, the executive vice president owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 54,057 shares of company stock worth $34,293,468. Company insiders own 0.98% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

Several large investors have recently made changes to their positions in IDXX. Select Equity Group L.P. lifted its stake in shares of IDEXX Laboratories by 23.7% in the 2nd quarter. Select Equity Group L.P. now owns 573,713 shares of the company’s stock valued at $307,705,000 after purchasing an additional 109,767 shares during the period. Sei Investments Co. lifted its stake in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of IDEXX Laboratories by 61.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 215,845 shares of the company’s stock valued at $115,766,000 after purchasing an additional 81,904 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $31,752,000. Finally, AQR Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 27.0% in the 2nd quarter. AQR Capital Management LLC now owns 223,319 shares of the company’s stock valued at $118,695,000 after purchasing an additional 47,534 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.